Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation

Journal of Clinical Oncology

Volumn 30, Issue 35, 2012, Pages 4427-4438

  Lehrnbecher, Thomas ^a   Phillips, Robert ^c,d   Alexander, Sarah ^f   Alvaro, Frank ^g   Carlesse, Fabianne ^h   Fisher, Brian ⁱ   Hakim, Hana ^j   Santolaya, Maria ^k   Castagnola, Elio ^l   Davis, Bonnie L ^m   Lee Dupuis, L ^f   Gibson, Faith ^e   Groll, Andreas H ^b   Gaur, Aditya ^j   Gupta, Ajay ⁿ   Kebudi, Rejin ^o   Petrilli, Sérgio ^h   Steinbach, William J ^p   Villarroel, Milena ^k   Zaoutis, Theoklis ⁱ   Sung, Lillian ^f   more..

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c LEEDS GENERAL INFIRMARY   (United Kingdom)

^d UNIVERSITY OF YORK   (United Kingdom)

^e LONDON SOUTH BANK UNIVERSITY   (United Kingdom)

^f HOSPITAL FOR SICK CHILDREN   (Canada)

^g JOHN HUNTER CHILDREN S HOSPITAL   (Australia)

^h FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

ⁱ CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^j ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^k UNIVERSITY OF CHILE   (Chile)

^l G GASLINI INSTITUTE   (Italy)

^m High Tor   (Bahamas)

ⁿ INSTITUTE ROTARY CANCER HOSPITAL   (India)

^o ISTANBUL UNIVERSITY   (Turkey)

^p DUKE UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT;

ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; CHILDHOOD CANCER; CLINICAL EVALUATION; EVIDENCE BASED MEDICINE; FEVER; HEALTH CARE MANAGEMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; NEUTROPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TREATMENT WITHDRAWAL;

EID: 84870755899     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.7161     Document Type: Review

References (140)

1. Freifeld AG, Bow EJ, Sepkowitz KA, et al: Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:e56-e93, 2011
2. Bucaneve G, Castagnola E, Viscoli C, et al: Quinolone prophylaxis for bacterial infections in afebrile high risk neutropenic patients. Eur J Cancer 5:5-12, 2007 (suppl) (Pubitemid 47187741)
3. Drgona L, Paul M, Bucaneve G, et al: The need for aminoglycosides in combination with β-lactams for high-risk, febrile neutropaenic patients with leukaemia. Eur J Cancer 5:13-22, 2007 (suppl) (Pubitemid 47189741)
4. Cometta A, Marchetti O, Calandra T: Empirical use of anti-Gram-positive antibiotics in febrile neutropaenic cancer patients with acute leukaemia. Eur J Cancer 5:23-31, 2007 (suppl) (Pubitemid 47187742)
5. Marchetti O, Cordonnier C, Calandra T: Empirical antifungal therapy in neutropaenic cancer patients with persistent fever. Eur J Cancer 5:32-42, 2007 (suppl) (Pubitemid 47187743)
6. National Comprehensive Cancer Network: NCCN Guidelines for Supportive Care: Prevention and Treatment of Cancer-Related Infections (Version 2.2011). http://www.nccn.org/professionals/physician-gls/f-guidelines.asp
7. de Naurois J, Novitzky-Basso I, Gill MJ, et al: Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol 21:v252-v256, 2010 (suppl 5)
8. Sung L, Phillips R, Lehrnbecher T: Time for paediatric febrile neutropenia guidelines: Children are not little adults. Eur J Cancer 47:811-813, 2011
9. Oxman AD, Fretheim A, Schünemann HJ: Improving the use of research evidence in guideline development: Introduction. Health Res Policy Syst 4:12, 2006
10. Brouwers MC, Kho ME, Browman GP, et al: Development of the AGREE II, part 1: Performance, usefulness and areas for improvement. CMAJ 182: 1045-1052, 2010
11. Brozek JL, Akl EA, Alonso-Coello P, et al: Grading quality of evidence and strength of recommendations in clinical practice guidelines: Part 1 of 3 - An overview of the GRADE approach and grading quality of evidence about interventions. Allergy 64:669-677, 2009
12. Rackoff WR, Gonin R, Robinson C, et al: Predicting the risk of bacteremia in children with fever and neutropenia. J Clin Oncol 14:919-924, 1996 (Pubitemid 26085537)
13. Alexander SW, Wade KC, Hibberd PL, et al: Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol 24:38-42, 2002 (Pubitemid 34094328)
14. Rondinelli PI, Ribeiro Kde C, de Camargo B: A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia. J Pediatr Hematol Oncol 28:665-670, 2006 (Pubitemid 44540164)
15. Santolaya ME, Alvarez AM, Becker A, et al: Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever. J Clin Oncol 19:3415-3421, 2001 (Pubitemid 32642195)
16. Ammann RA, Hirt A, Lüthy AR, et al: Identification of children presenting with fever in chemotherapy-induced neutropenia at low risk for severe bacterial infection. Med Pediatr Oncol 41:436-443, 2003 (Pubitemid 37229435)
17. Ammann RA, Bodmer N, Hirt A, et al: Predicting adverse events in children with fever and chemotherapy-induced neutropenia: The prospective multicenter SPOG 2003 FN study. J Clin Oncol 28:2008-2014, 2010
18. Madsen K, Rosenman M, Hui S, et al: Value of electronic data for model validation and refinement: Bacteremia risk in children with fever and neutropenia. J Pediatr Hematol Oncol 24:256-262, 2002 (Pubitemid 34506611)
19. Dommett R, Geary J, Freeman S, et al: Successful introduction and audit of a step-down oral antibiotic strategy for low risk paediatric febrile neutropaenia in a UK, multicentre, shared care setting. Eur J Cancer 45:2843-2849, 2009
20. Santolaya ME, Alvarez AM, Avilés CL, et al: Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer, fever, and neutropenia. Clin Infect Dis 35: 678-683, 2002 (Pubitemid 35024727)
21. Macher E, Dubos F, Garnier N, et al: Predicting the risk of severe bacterial infection in children with chemotherapy-induced febrile neutropenia. Pediatr Blood Cancer 55:662-667, 2010
22. Miedema KG, de Bont ES, Oude Nijhuis CS, et al: Validation of a new risk assessment model for predicting adverse events in children with fever and chemotherapy-induced neutropenia. J Clin Oncol 29:e182-e184, 2011
23. Agyeman P, Aebi C, Hirt A, et al: Predicting bacteremia in children with cancer and fever in chemotherapy-induced neutropenia: Results of the prospective multicenter SPOG 2003 FN study. Pediatr Infect Dis J 30:e114-e119, 2011
24. Ammann RA, Aebi C, Hirt A, et al: Fever in neutropenia in children and adolescents: Evolution over time of main characteristics in a single center, 1993-2001. Support Care Cancer 12:826-832, 2004 (Pubitemid 40104776)
25. Baorto EP, Aquino VM, Mullen CA, et al: Clinical parameters associated with low bacteremia risk in 1100 pediatric oncology patients with fever and neutropenia. Cancer 92:909-913, 2001 (Pubitemid 32783080)
26. Hakim H, Flynn PM, Srivastava DK, et al: Risk prediction in pediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J 29:53-59, 2010
27. Hann I, Viscoli C, Paesmans M, et al: A comparison of outcome from febrile neutropenic episodes in children compared with adults: Results from four EORTC studies-International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organisation for Research and Treatment of Cancer (EORTC). Br J Haematol 99:580-588, 1997
28. Jones GR, Konsler GK, Dunaway RP, et al: Infection risk factors in febrile, neutropenic children and adolescents. Pediatr Hematol Oncol 13:217-229, 1996 (Pubitemid 26146273)
29. Klaassen RJ, Goodman TR, Pham B, et al: "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol 18:1012-1019, 2000 (Pubitemid 30123777)
30. Lucas KG, Brown AE, Armstrong D, et al: The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis. Cancer 77:791-798, 1996 (Pubitemid 26055407)
31. Paganini HR, Aguirre C, Puppa G, et al: A prospective, multicentric scoring system to predict mortality in febrile neutropenic children with cancer. Cancer 109:2572-2579, 2007 (Pubitemid 46906478)
32. Tezcan G, Kupesiz A, Ozturk F, et al: Episodes of fever and neutropenia in children with cancer in a tertiary care medical center in Turkey. Pediatr Hematol Oncol 23:217-229, 2006 (Pubitemid 43361804)
33. West DC, Marcin JP, Mawis R, et al: Children with cancer, fever, and treatment-induced neutropenia: Risk factors associated with illness requiring the administration of critical care therapies. Pediatr Emerg Care 20:79-84, 2004 (Pubitemid 38235414)
34. Phillips B, Wade R, Stewart LA, et al: Systematic review and meta-analysis of the discriminatory performance of risk prediction rules in febrile neutropaenic episodes in children and young people. Eur J Cancer 46:2950-2964, 2010
35. Toll DB, Janssen KJ, Vergouwe Y, et al: Validation, updating and impact of clinical prediction rules: A review. J Clin Epidemiol 61:1085-1094, 2008
36. Phillips R, Lehrnbecher T, Alexander S, et al: Updated systematic review and meta-analysis of the performance of risk prediction rules in children and young people with febrile neutropenia. PLoS One 7:e38300, 2012
37. Scheinemann K, Ethier MC, Dupuis LL, et al: Utility of peripheral blood cultures in bacteremic pediatric cancer patients with a central line. Support Care Cancer 18:913-919, 2010
38. DesJardin JA, Falagas ME, Ruthazer R, et al: Clinical utility of blood cultures drawn from indwelling central venous catheters in hospitalized patients with cancer. Ann Intern Med 131:641-647, 1999 (Pubitemid 29517948)
39. Chen WT, Liu TM, Wu SH, et al: Improving diagnosis of central venous catheter-related bloodstream infection by using differential time to positivity as a hospital-wide approach at a cancer hospital. J Infect 59:317-323, 2009
40. Adamkiewicz TV, Lorenzana A, Doyle J, et al: Peripheral vs. central blood cultures in patients admitted to a pediatric oncology ward. Pediatr Infect Dis J 18:556-558, 1999 (Pubitemid 29277625)
41. Raad I, Hanna HA, Alakech B, et al: Differential time to positivity: A useful method for diagnosing catheter-related bloodstream infections. Ann Intern Med 140:18-25, 2004
42. Handrup MM, Moller JK, Schroder H: Catheter-related bloodstream infections in children with cancer admitted with fever. Presented at the 42nd Congress of the International Society of Pediatric Oncology, Boston, MA, October 21-24, 2010
43. Barriga FJ, Varas M, Potin M, et al: Efficacy of a vancomycin solution to prevent bacteremia associated with an indwelling central venous catheter in neutropenic and non-neutropenic cancer patients. Med Pediatr Oncol 28:196-200, 1997 (Pubitemid 27078422)
44. O'Grady NP, Alexander M, Burns LA, et al: Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control 39: S1-S34, 2011 (suppl 1)
45. Wilson ML, Mitchell M, Morris AJ, et al: Principles and Procedures for Blood Cultures: Approved Guideline-CLSI Document M47-A. Wayne, PA, Clinical and Laboratory Standards Institute, 2007
46. Isaacman DJ, Karasic RB, Reynolds EA, et al: Effect of number of blood cultures and volume of blood on detection of bacteremia in children. J Pediatr 128:190-195, 1996 (Pubitemid 26065941)
47. Kellogg JA, Manzella JP, Bankert DA: Frequency of low-level bacteremia in children from birth to fifteen years of age. J Clin Microbiol 38:2181-2185, 2000 (Pubitemid 30414335)
48. Connell TG, Rele M, Cowley D, et al: How reliable is a negative blood culture result? Volume of blood submitted for culture in routine practice in a children's hospital. Pediatrics 119:891-896, 2007 (Pubitemid 46715658)
49. Gaur AH, Giannini MA, Flynn PM, et al: Optimizing blood culture practices in pediatric immunocompromised patients: Evaluation of media types and blood culture volume. Pediatr Infect Dis J 22:545-552, 2003 (Pubitemid 36782195)
50. Klaassen IL, de Haas V, van Wijk JA, et al: Pyuria is absent during urinary tract infections in neutropenic patients. Pediatr Blood Cancer 56:868- 870, 2011
51. Mori R, Yonemoto N, Fitzgerald A, et al: Diagnostic performance of urine dipstick testing in children with suspected UTI: A systematic review of relationship with age and comparison with microscopy. Acta Paediatr 99:581-584, 2010
52. Sickles EA, Greene WH, Wiernik PH: Clinical presentation of infection in granulocytopenic patients. Arch Intern Med 135:715-719, 1975
53. Feusner J, Cohen R, O'Leary M, et al: Use of routine chest radiography in the evaluation of fever in neutropenic pediatric oncology patients. J Clin Oncol 6:1699-1702, 1988 (Pubitemid 19089047)
54. Katz JA, Bash R, Rollins N, et al: The yield of routine chest radiography in children with cancer hospitalized for fever and neutropenia. Cancer 68: 940-943, 1991
55. Korones DN, Hussong MR, Gullace MA: Routine chest radiography of children with cancer hospitalized for fever and neutropenia: Is it really necessary? Cancer 80:1160-1164, 1997 (Pubitemid 27427617)
56. Renoult E, Buteau C, Turgeon N, et al: Is routine chest radiography necessary for the initial evaluation of fever in neutropenic children with cancer? Pediatr Blood Cancer 43:224-228, 2004 (Pubitemid 39025303)
57. Phillips R, Wade R, Riley R, et al: Systematic review and meta-analysis of the value of clinical features to exclude radiographic pneumonia in febrile neutropenic episodes in children and young people. J Paediatr Child Health, 2011
58. Furno P, Bucaneve G, Del Favero A: Monotherapy or aminoglycoside- containing combinations for empirical antibiotic treatment of febrile neutropenic patients: A meta-analysis. Lancet Infect Dis 2:231-242, 2002 (Pubitemid 34464753)
59. Paul M, Soares-Weiser K, Leibovici L: Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: Systematic review and meta-analysis. BMJ 326: 1111, 2003
60. Manji A, Lehrnbecher T, Dupuis LL, et al: A systematic review and meta-analysis of antipseudomonal penicillins and carbapenems in pediatric febrile neutropenia. Support Care Cancer [epub ahead of print on December 6, 2011]
61. Manji A, Lehrnbecher T, Dupuis LL, et al: A meta-analysis of antipseudomonal penicillins and cephalosporins in pediatric patients with fever and neutropenia. Pediatr Infect Dis J 31:353-358, 2012
62. Paul M, Yahav D, Bivas A, et al: Antipseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: Comparison of beta-lactams. Cochrane Database Syst Rev 11: CD005197, 2010
63. Kim PW, Wu YT, Cooper C, et al: Metaanalysis of a possible signal of increased mortality associated with cefepime use. Clin Infect Dis 51: 381-389, 2010
64. Marron A, Carratalà J, Alcaide F, et al: High rates of resistance to cephalosporins among viridans-group streptococci causing bacteraemia in neutropenic cancer patients. J Antimicrob Chemother 47:87-91, 2001
65. Vardakas KZ, Samonis G, Chrysanthopoulou SA, et al: Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: A meta-analysis of randomised controlled trials. Lancet Infect Dis 5:431-439, 2005 (Pubitemid 40846470)
66. Speyer E, Herbinet A, Vuillemin A, et al: Agreement between children with cancer and their parents in reporting the child's health-related quality of life during a stay at the hospital and at home. Child Care Health Dev 35:489-495, 2009
67. Teuffel O, Amir E, Alibhai SM, et al: Costeffectiveness of outpatient management for febrile neutropenia in children with cancer. Pediatrics 127: e279-e286, 2011
68. Teuffel O, Ethier MC, Alibhai SM, et al: Outpatient management of cancer patients with febrile neutropenia: A systematic review and metaanalysis. Ann Oncol 22:2358-2365, 2011
69. Ahmed N, El-Mahallawy HA, Ahmed IA, et al: Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: A randomized, prospective study. Pediatr Blood Cancer 49:786-792, 2007 (Pubitemid 47519513)
70. Santolaya ME, Alvarez AM, Avilés CL, et al: Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. J Clin Oncol 22:3784-3789, 2004 (Pubitemid 41095219)
71. Manji A, Beyene J, Dupuis LL, et al: Outpatient and oral antibiotic management of low-risk febrile neutropenia are effective in children: A systematic review of prospective trials. Support Care Cancer 20:1135-1145, 2012
72. Vidal L, Paul M, Ben-Dor I, et al: Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane Database Syst Rev 4:CD003992, 2004
73. Cometta A, Kern WV, De Bock R, et al: Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 37:382-389, 2003 (Pubitemid 36976496)
74. Oude Nijhuis C, Kamps WA, Daenen SM, et al: Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. J Clin Oncol 23:7437-7444, 2005 (Pubitemid 46291805)
75. Aquino VM, Buchanan GR, Tkaczewski I, et al: Safety of early hospital discharge of selected febrile children and adolescents with cancer with prolonged neutropenia. Med Pediatr Oncol 28:191-195, 1997 (Pubitemid 27078421)
76. Pizzo PA, Robichaud KJ, Gill FA, et al: Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med 67:194-200, 1979 (Pubitemid 9239511)
77. Santolaya ME, Villarroel M, Avendaño LF, et al: Discontinuation of antimicrobial therapy for febrile, neutropenic children with cancer: A prospective study. Clin Infect Dis 25:92-97, 1997 (Pubitemid 27293081)
78. Wacker P, Halperin DS, Wyss M, et al: Early hospital discharge of children with fever and neutropenia: A prospective study. J Pediatr Hematol Oncol 19:208-211, 1997 (Pubitemid 27276286)
79. Cohen KJ, Leamer K, Odom L, et al: Cessation of antibiotics regardless of ANC is safe in children with febrile neutropenia: A preliminary prospective trial. J Pediatr Hematol Oncol 17:325-330, 1995
80. Bash RO, Katz JA, Cash JV, et al: Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia. Cancer 74:189-196, 1994 (Pubitemid 24187629)
81. Hodgson-Viden H, Grundy PE, Robinson JL: Early discontinuation of intravenous antimicrobial therapy in pediatric oncology patients with febrile neutropenia. BMC Pediatr 5:10, 2005
82. Lehrnbecher T, Stanescu A, Kühl J: Short courses of intravenous empirical antibiotic treatment in selected febrile neutropenic children with cancer. Infection 30:17-21, 2002 (Pubitemid 34146407)
83. Griffin TC, Buchanan GR: Hematologic predictors of bone marrow recovery in neutropenic patients hospitalized for fever: Implications for discontinuation of antibiotics and early discharge from the hospital. J Pediatr 121:28-33, 1992
84. Kaplan AH, Weber DJ, Davis L, et al: Short courses of antibiotics in selected febrile neutropenic patients. Am J Med Sci 302:353-354, 1991
85. Mullen CA, Buchanan GR: Early hospital discharge of children with cancer treated for fever and neutropenia: Identification and management of the low-risk patient. J Clin Oncol 8:1998-2004, 1990
86. Aquino VM, Tkaczewski I, Buchanan GR: Early discharge of low-risk febrile neutropenic children and adolescents with cancer. Clin Infect Dis 25:74-78, 1997 (Pubitemid 27293077)
87. Slobbe L, Waal L, Jongman LR, et al: Threeday treatment with imipenem for unexplained fever during prolonged neutropaenia in haematology patients receiving fluoroquinolone and fluconazole prophylaxis: A prospective observational safety study. Eur J Cancer 45:2810-2817, 2009
88. Cornelissen JJ, Rozenberg-Arska M, Dekker AW: Discontinuation of intravenous antibiotic therapy during persistent neutropenia in patients receiving prophylaxis with oral ciprofloxacin. Clin Infect Dis 21:1300-1302, 1995
89. de Marie S, van den Broek PJ, Willemze R, et al: Strategy for antibiotic therapy in febrile neutropenic patients on selective antibiotic decontamination. Eur J Clin Microbiol Infect Dis 12:897-906, 1993 (Pubitemid 24025867)
90. Joshi JH, Schimpff SC, Tenney JH, et al: Can antibacterial therapy be discontinued in persistently febrile granulocytopenic cancer patients? Am J Med 76:450-457, 1984 (Pubitemid 14159556)
91. Björnsson S, Preisler H, Henderson ES: A study of antibiotic therapy in fever of unknown origin in neutropenic cancer patients. Med Pediatr Oncol 3:379-385, 1977 (Pubitemid 8235410)
92. Mahendra P, Jacobson SK, Ager S, et al: Short-course intravenous antibiotics with oral quinolone prophylaxis in the treatment of neutropenic fever in autologous bone marrow or peripheral blood progenitor cell transplant recipients. Acta Haematol 96:64-67, 1996 (Pubitemid 26245658)
93. Tomiak AT, Yau JC, Huan SD, et al: Duration of intravenous antibiotics for patients with neutropenic fever. Ann Oncol 5:441-445, 1994 (Pubitemid 24159650)
94. Groll AH, Kurz M, Schneider W, et al: Five-year-survey of invasive aspergillosis in a paediatric cancer centre: Epidemiology, management and long-term survival. Mycoses 42:431-442, 1999 (Pubitemid 29470384)
95. Zaoutis TE, Heydon K, Chu JH, et al: Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics 117:e711-e716, 2006 (Pubitemid 46071475)
96. Leahey AM, Bunin NJ, Belasco JB, et al: Novel multiagent chemotherapy for bone marrow relapse of pediatric acute lymphoblastic leukemia. Med Pediatr Oncol 34:313-318, 2000 (Pubitemid 30230605)
97. Mor M, Gilad G, Kornreich L, et al: Invasive fungal infections in pediatric oncology. Pediatr Blood Cancer 56:1092-1097, 2011
98. Rosen GP, Nielsen K, Glenn S, et al: Invasive fungal infections in pediatric oncology patients: 11-year experience at a single institution. J Pediatr Hematol Oncol 27:135-140, 2005 (Pubitemid 40397242)
99. Castagnola E, Cesaro S, Giacchino M, et al: Fungal infections in children with cancer: A prospective, multicenter surveillance study. Pediatr Infect Dis J 25:634-639, 2006 (Pubitemid 43995362)
100. Hovi L, Saarinen-Pihkala UM, Vettenranta K, et al: Invasive fungal infections in pediatric bone marrow transplant recipients: Single center experience of 10 years. Bone Marrow Transpl 26:999-1004, 2000
101. Villarroel M, Avilés CL, Silva P, et al: Risk factors associated with invasive fungal disease in children with cancer and febrile neutropenia: A prospective multicenter evaluation. Pediatr Infect Dis J 29:816-821, 2010
102. Afzal S, Ethier MC, Dupuis LL, et al: Risk factors for infection-related outcomes during induction therapy for childhood acute lymphoblastic leukemia. Pediatr Infect Dis J 28:1064-1068, 2009
103. Haupt R, Romanengo M, Fears T, et al: Incidence of septicaemias and invasive mycoses in children undergoing treatment for solid tumours: A 12-year experience at a single Italian institution. Eur J Cancer 37:2413-2419, 2001 (Pubitemid 33097479)
104. Grigull L, Beier R, Schrauder A, et al: Invasive fungal infections are responsible for one-fifth of the infectious deaths in children with ALL. Mycoses 46:441-446, 2003 (Pubitemid 38005338)
105. Panackal AA, Li H, Kontoyiannis D, et al: Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation. Clin Infect Dis 50:1588-1597, 2010
106. Haiduven D: Nosocomial aspergillosis and building construction. Med Mycol 47:S210-S216, 2009 (suppl 1)
107. De Pauw B, Walsh TJ, Donnelly JP, et al: Revised definitions of invasive fungal disease from the European Organisation for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46:1813-1821, 2008
108. Rohrlich P, Sarfati J, Mariani P, et al: Prospective sandwich enzyme-linked immunosorbent assay for serum galactomannan: Early predictive value and clinical use in invasive aspergillosis. Pediatr Infect Dis J 15:232-237, 1996 (Pubitemid 26098473)
109. El-Mahallawy HA, Shaker HH, Ali Helmy H, et al: Evaluation of pan-fungal PCR assay and aspergillus antigen detection in the diagnosis of invasive fungal infections in high risk paediatric cancer patients. Med Mycol 44:733-739, 2006 (Pubitemid 44824451)
110. Hovi L, Saxen H, Saarinen-Pihkala UM, et al: Prevention and monitoring of invasive fungal infections in pediatric patients with cancer and hematologic disorders. Pediatr Blood Cancer 48:28-34, 2007 (Pubitemid 44871589)
111. Steinbach WJ, Addison RM, McLaughlin L, et al: Prospective aspergillus galactomannan antigen testing in pediatric hematopoietic stem cell transplant recipients. Pediatr Infect Dis J 26:558-564, 2007 (Pubitemid 47014154)
112. Hayden R, Pounds S, Knapp K, et al: Galactomannan antigenemia in pediatric oncology patients with invasive aspergillosis. Pediatr Infect Dis J 27:815-819, 2008
113. Armenian SH, Nash KA, Kapoor N, et al: Prospective monitoring for invasive aspergillosis using galactomannan and polymerase chain reaction in high risk pediatric patients. J Pediatr Hematol Oncol 31:920-926, 2009
114. Castagnola E, Furfaro E, Caviglia I, et al: Performance of the galactomannan antigen detection test in the diagnosis of invasive aspergillosis in children with cancer or undergoing haemopoietic stem cell transplantation. Clin Microbiol Infect 16: 1197-1203, 2010
115. Challier S, Boyer S, Abachin E, et al: Development of a serum-based Taqman real-time PCR assay for diagnosis of invasive aspergillosis. J Clin Microbiol 42:844-846, 2004 (Pubitemid 38222678)
116. Pfeiffer CD, Fine JP, Safdar N: Diagnosis of invasive aspergillosis using a galactomannan assay: A meta-analysis. Clin Infect Dis 42:1417-1427, 2006
117. Maertens J, Maertens V, Theunissen K, et al: Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin Infect Dis 49:1688-1693, 2009
118. Desai R, Ross LA, Hoffman JA: The role of bronchoalveolar lavage galactomannan in the diagnosis of pediatric invasive aspergillosis. Pediatr Infect Dis J 28:283-286, 2009
119. Roilides E, Pavlidou E, Papadopoulos F, et al: Cerebral aspergillosis in an infant with corticosteroid-resistant nephrotic syndrome. Pediatr Nephrol 18:450-453, 2003 (Pubitemid 36798489)
120. Viscoli C, Machetti M, Gazzola P, et al: Aspergillus galactomannan antigen in the cerebrospinal fluid of bone marrow transplant recipients with probable cerebral aspergillosis. J Clin Microbiol 40: 1496-1499, 2002 (Pubitemid 34279924)
121. Karageorgopoulos DE, Vouloumanou EK, Ntziora F, et al: β-D-glucan assay for the diagnosis of invasive fungal infections: A meta-analysis. Clin Infect Dis 52:750-770, 2011
122. Mularoni A, Furfaro E, Faraci M, et al: High Levels of beta-D-glucan in immunocompromised children with proven invasive fungal disease. Clin Vaccine Immunol 17:882-883, 2010
123. Zhao L, Tang JY, Wang Y, et al: Value of plasma β-glucan in early diagnosis of invasive fungal infection in children. Chin J Contemp Pediatr 11: 905-908, 2009
124. Smith PB, Benjamin DK Jr, Alexander BD, et al: Quantification of 1,3-beta-D-glucan levels in children: Preliminary data for diagnostic use of the beta-glucan assay in a pediatric setting. Clin Vaccine Immunol 14:924-925, 2007
125. Heussel CP, Kauczor HU, Heussel GE, et al: Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: Use of high-resolution computed tomography. J Clin Oncol 17:796-805, 1999 (Pubitemid 29109308)
126. Caillot D, Casasnovas O, Bernard A, et al: Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 15:139-147, 1997 (Pubitemid 27020567)
127. Taccone A, Occhi M, Garaventa A, et al: CT of invasive pulmonary aspergillosis in children with cancer. Pediatr Radiol 23:177-180, 1993 (Pubitemid 23220506)
128. Burgos A, Zaoutis TE, Dvorak CC, et al: Pediatric invasive aspergillosis: A multicenter retrospective analysis of 139 contemporary cases. Pediatrics 121:e1286-e1294, 2008
129. Archibald S, Park J, Geyer JR, et al: Computed tomography in the evaluation of febrile neutropenic pediatric oncology patients. Pediatr Infect Dis J 20:5-10, 2001 (Pubitemid 32066169)
130. Agrawal AK, Saini N, Gildengorin G, et al: Is routine computed tomographic scanning justified in the first week of persistent febrile neutropenia in children with malignancies? Pediatr Blood Cancer 57:620-624, 2011
131. Sörensen J, Becker M, Porto L, et al: Rhinocerebral zygomycosis in a young girl undergoing allogeneic stem cell transplantation for severe aplastic anaemia. Mycoses 49:31-36, 2006 (suppl 1)
132. Rassi SJ, Melkane AE, Rizk HG, et al: Sinonasal mucormycosis in immunocompromised pediatric patients. J Pediatr Hematol Oncol 31:907-910, 2009
133. Flynn PM, Shenep JL, Crawford R, et al: Use of abdominal computed tomography for identifying disseminated fungal infection in pediatric cancer patients. Clin Infect Dis 20:964-970, 1995
134. Bochennek K, Abolmaali N, Wittekindt B, et al: Diagnostic approaches for immunocompromised paediatric patients with pulmonary infiltrates. Clin Microbiol Infect 12:199-201, 2006 (Pubitemid 43379318)
135. Prentice HG, Hann IM, Herbrecht R, et al: A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 98:711-718, 1997 (Pubitemid 27386554)
136. Maertens JA, Madero L, Reilly AF, et al: A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J 29:415-420, 2010
137. Sandler ES, Mustafa MM, Tkaczewski I, et al: Use of amphotericin B colloidal dispersion in children. J Pediatr Hematol Oncol 22:242-246, 2000 (Pubitemid 32268308)
138. Walsh TJ, Teppler H, Donowitz GR, et al: Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351:1391-1402, 2004
139. White MH, Bowden RA, Sandler ES, et al: Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 27:296-302, 1998 (Pubitemid 28365752)
140. Walsh TJ, Finberg RW, Arndt C, et al: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia: National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 340:764-771, 1999 (Pubitemid 29114295)